Altor Bioscience Corporation
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14
Ending by 2030
May 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 13 to 20, 2026 · next Dec 13
- 1 fee due Jan 23, 2027The maintenance fee for Multimeric IL-15 Soluble Fusion Molecules and Methods of Making and Using Same (US 10,358,478) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for IL-15 Variants and Uses Thereof (US 10,450,359) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Multimeric IL-15 Soluble Fusion Molecules and Methods of Making and Using Same (US 11,845,783) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 2 fees due Jul 16 to 21, 2027 · next Jul 16
- 2 fees due Aug 6 to 9, 2027 · next Aug 6
- 1 fee due Sep 12, 2027The maintenance fee for Method for Treating Neoplasia with an ANTI-CD38 Antibody and an IL-15:IL-15R Complex (US 11,925,676) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for IL-15-Based Fusions to IL-7 and IL-21 (US 11,965,007) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 2 fees due Nov 3 to 7, 2027 · next Nov 3
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,163,879 | Fusion Molecules and IL-15 Variants In force · High confidence | In force | High confidence | |
| US 8,940,289 | Fusion Molecules and IL-15 Variants In force · High confidence | In force | High confidence | |
| US 9,593,152 | Methods of Treating Disease with Fusion Molecules Comprising IL-15 Variants In force · High confidence | In force | High confidence | |
| US 10,450,359 | IL-15 Variants and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,365,231 | Interleukin 15 (IL-15) Variants In force · High confidence | In force | High confidence | |
| US 11,498,950 | Fusion Molecules and IL-15 Variants In force · Medium confidence | In force | Medium confidence | |
| US 11,673,932 | Fusion Molecules and IL-15 Variants In force · Medium confidence | In force | Medium confidence | |
| US 12,168,680 | Fusion Molecules and IL-15 Variants In force · Medium confidence | In force | Medium confidence | |
| US 9,464,127 | Fusion Molecules and IL-15 Variants In force · Medium confidence | In force | Medium confidence | |
| US 11,261,231 | Methods for Inhibiting HIV or HCV Infection by Administering TIM-3 Binding Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 54: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 14 abandoned · 6 no status recorded